Acta Scientific Computer Sciences

Review Article Volume 3 Issue 11

Hemorrhagic Stroke in 2021

Adel Ekladious1,2*

1Associate Professor of Medicine, Faculty of Health and Medical science, University of Western Australia, Australia
2Bega-South East Regional hospital, NSW , Australia

*Corresponding Author: Adel Ekladious, Associate Professor of Medicine, Faculty of Health and Medical science, University of Western Australia, Australia and Bega-South East Regional hospital, NSW , Australia.
Email: ekladiou@gmail.com

Received: September 09, 2021; Published: October 22, 2021

Abstract

Spontaneous cerebral bleed is a life threatening condition and should be managed as an emergency, Mortality in the first 30 days are extremely high, although there is no significant progress in treatment, Patient should be treated actively in the first 72 hours, and no orders not for recuses should be made, Early diagnosis and treatment is of paramount importance to arrest rapid expansion of bleed, prevent neurological deterioration, morbidity and death. Controlling blood pressure, reversing anticoagulation, endovascular treatment for subarachnoid bleed, decompression of posterior fossa in cerebellar bleed. Can prevent mortality and morbidity.

Keywords: Spontaneous Cerebral; Hemorrhagic Stroke; Neurology

Bibliography

  1. Feigin VL., et al. “Worldwide stroke incidence and early fatality reported in 56 population-based studies: a systemic review”. Lancet Neurology 8 (2009): 355-369.
  2. AL-Shahi Salman R., et al. “Absolute risk and predictors of the growth of acute spontaneous intracerebral hemorrhage: a systemic review and meta-analysis of individual patient Data”. Lancet Neurology 17 (2018): 885-894.
  3. Jolink WM., et al. “Time trends in incidence, case fatality, and mortality of intracerebral hemorrhage”. Neurology 85 (2015): 1318-1324.
  4. Delgado Amandoz JE., et al. “The spot sign score in primary intracerebral hemorrhage identifies patients at highest risk on in hospital mortality and poor outcome among Survivors”. Stroke 41 (2010): 54-60.
  5. An SJ., et al. “Epidemiology, Risk factors, and clinical features of intracerebral Hemorrhage: An Update”. Journal of Stroke1 (2017) :3-10.
  6. Van Asch CJ., et al. “Incidence, case fatality and function outcome of intracerebral hemorrhage over time, according to age, sex, and ethnic origin: A systemic Review and meta-analysis”. Lancet Neurology 9 (2010): 167-176.
  7. Muntuner P., et al. “Potential US population impact of the 2017 ACC/AHA, High blood pressure guideline”. Circulation2 (2018): 109-118.
  8. AL-Shahi R. “A systematic review of the frequency and diagnosis of arteriovenous malformation of the brain in adults”. Brain 124 (2001): 1900-192.
  9. Let Alinn J., et al. “Prevalence of superficial siderosis in patients with cerebral amyloid angiopathy”. Neurology 74 (2010): 1346-1350.
  10. Kim HT., et al. “Surgery versus conservative treatment for spontaneous supratentorial intracerebral hemorrhage in spot sign positive patients”. Journal of Korean Neurosurgery Society 58 (2015): 309-315.
  11. Li Q., et al. “Blend sign predicts poor outcome in patients with intracerebral Hemorrhage”. PLos One 12 (2017): e0183082.
  12. Sporns PB., et al. “Computed tomographic Blend sign is Associated with CTA spot sign and predicts secondary Neurological deterioration after intracerebral Hemorrhage”. Stroke 1 (2017): 131-135.
  13. Macellari F., et al. “Neuroimaging in intracerebral Hemorrhage”. Stroke 3 (2014): 903-908.
  14. Steiner T., et al. “Fresh frozen Plasma versus prothrombin complex in patients with intracranial Hemorrhage related to vitamin K antagonists: a randomized trial”. Lancet Neurology 15 (2016): 566-573.
  15. Hemphill JC., et al. “Guidelines for the management for spontaneous intracerebral hemorrhage: s Guideline for healthcare professionals from American Heart Association/American Stroke Association”. Stroke 46 (2015): 2032-2060.
  16. Baharoglu MI., et al. “Platelets transfusion versus standard care after acute stroke due to spontaneous cerebral hemorrhage associated with antiplanet therapy (PATCH): A randomized, open label phase3 trial”. Lancet10038 (2016): 2605-2613.
  17. Naidech AM., et al. “Reduced platelet activity is associated with early Clot growth and worse 3-month outcome after intracerebral hemorrhage”. Stroke 40 (2009): 2398-2401.
  18. Sprigg N., et al. “Tranexamic acid for hyper acute primary intracerebral hemorrhage (TICH 2): an international placebo-controlled phase 3 trial superiority”. Lancet 391 (2018): 2107-2115.
  19. Qureshi AL., et al. “Intracerebral hemorrhage”. Lancet 373 (2009): 1632-1644.
  20. Cervoni LR., et al. “Epileptic Seizures in intracerebral hemorrhage: A clinical and diagnostic study of 55 cases”. Neurosurgery Review 17 (1994): 185-188.
  21. Kelly J., et al. “Venous Thromboembolism after acute stroke”. Stroke 32 (2001): 262-267.
  22. Kuramatsu JB., et al. “Association of surgical hematoma Evacuation VS Conservative Management Treatment with Functional outcome in patients with Cerebellar intracerebral hemorrhage”. JAMA 322 (2019): 1392.
  23. Da Rian R., et al. “Surgical versus medical treatment of Spontaneous posterior fossa Hematoma: cooperative study on 250 cases”. Neurology Research 6 (1984): 145.
  24. Hanger HC., et al. “Effect of aspirin N and warfarin on early survival after intracerebral Hemorrhage”. Journal of Neurology 255 (2008): 347-325.

Citation

Citation: Adel Ekladious. “Hemorrhagic Stroke in 2021". Acta Scientific Computer Sciences 3.11 (2021): 139-142.

Copyright

Copyright: © 2021 Adel Ekladious. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.




Metrics

Acceptance rate30%
Acceptance to publication20-30 days
Impact Factor1.403

Indexed In





Contact US